Hemodiafiltration with on-line production of substitution fluid: long-term safety and quantitative assessment of efficacy.
Canaud
B
B
Lapeyronie University Hospital, Montpellier, France.
Flavier
J L
JL
Argilés
A
A
Stec
F
F
NGuyen
Q V
QV
Bouloux
C
C
Garred
L J
LJ
Mion
C
C
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001419:Bacteria / Q000302:isolation & purification; D001639:Bicarbonates; D001823:Body Composition; D003404:Creatinine / Q000097:blood; D004203:Disinfection; D004340:Drug Contamination; D004866:Equipment Contamination; D004921:Erythropoietin / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D017583:Hemodiafiltration / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D015312:Hemodialysis Solutions; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D012449:Safety; D014508:Urea / Q000097:blood; D014871:Water Microbiology
D000959:Antihypertensive Agents; D001639:Bicarbonates; D015312:Hemodialysis Solutions; D007155:Immunologic Factors; D008567:Membranes, Artificial; D011994:Recombinant Proteins; D004921:Erythropoietin; D014508:Urea; D003404:Creatinine